Cornerstone Capital Inc. reduced its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.2% in the 3rd quarter, Holdings Channel reports. The fund owned 151,329 shares of the company’s stock after selling 3,427 shares during the period. AbbVie makes up 3.5% of Cornerstone Capital Inc.’s investment portfolio, making the stock its 8th largest position. Cornerstone Capital Inc.’s holdings in AbbVie were worth $39,586,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the stock. State Street Corp grew its stake in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Fisher Asset Management LLC increased its holdings in shares of AbbVie by 252.6% during the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares in the last quarter. Corient Private Wealth LP purchased a new position in shares of AbbVie during the 2nd quarter valued at approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of AbbVie in the 2nd quarter valued at $2,905,952,000. 70.23% of the stock is owned by institutional investors and hedge funds.
AbbVie Trading Down 0.3%
Shares of ABBV opened at $294.18 on Tuesday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93. The stock’s 50 day moving average is $276.27 and its two-hundred day moving average is $241.28. The firm has a market cap of $520.00 billion, a P/E ratio of 50.63, a PEG ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.86 earnings per share. Equities research analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.
AbbVie Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a $1.82 dividend. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is 125.30%.
Wall Street Analysts Forecast Growth
ABBV has been the topic of a number of recent analyst reports. The Goldman Sachs Group increased their price target on shares of AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a report on Friday, October 23rd. Canaccord Genuity Group raised their price target on shares of AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Scotiabank lifted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. UBS Group upped their price objective on shares of AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. Finally, Barclays upped their price objective on shares of AbbVie from $325.00 to $335.00 and gave the stock an “overweight” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $297.85.
Read Our Latest Stock Report on AbbVie
Insider Transactions at AbbVie
In related news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Recommended Stories
- Five stocks we like better than AbbVie
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
